Combination of sST2 and BNP in Predicting the Mortality of ST-Elevation Myocardial Infarction

Abstract

Serum levels of ST2 are associated with prognosis in non-ischemic heart failure, but the predictive value of ST2 in patients with ST elevation myocardial infarction is unknown. Methods The study included 38 STEMI patients at Interventional Cardiology department of Cho Ray hospital. Correlation analysis was used to identify the relationship between the cardiac outcomes within 30 days from the onset of chest pain and sST2 value. Results ST2 levels were measured in serum from 38 patients with STEMI. Baseline levels of ST2 were significantly higher in those patients who died (<35 ng/mL vs. >35 ng/mL, P = 0.01) or developed new congestive heart failure (<35 ng/mL vs. >35 ng/mL, P = 0.002) by 30 days. In an analysis of outcomes at 30 days by ST2 quartiles, both death (P = 0.01) and the combined death/heart failure end point (p = 0.001) showed a significant graded association with levels of ST2. Furthermore, when sST2 > 35 ng/mL and BNP > 500 pg/mL showed a tightly relationship with cardiac outcomes within 30 days (P < 0.0001). Conclusions Serum levels of the interleukin-1 receptor family member ST2 predict mortality and heart failure in patients with STEMI. These data suggest that ST2 and BNP are the useful biomarker in short-term prognosis of cardiac events in STEMI.